Quintiles Acquires Outcome Sciences, Inc., Premier Observational Research Company
With late phase (Phase IIIB and Phase IV) research becoming increasingly important to multiple healthcare stakeholders, Quintiles announced it has acquired Outcome Sciences, Inc. (Outcome), a privately held outcomes research firm headquartered in Cambridge, Mass.
Outcome is a provider of observational research services. Observational research encompasses registries, post-approval research and quality improvement initiatives across multiple healthcare stakeholders (biopharmaceutical, medical device, government and providers). Since its founding in 1998, Outcome has designed, developed and managed more patient registries and post-approval studies than any other company. Outcome’s programs across more than 40 therapeutic areas include thousands of sites and millions of patients in more than 80 countries.
“This acquisition underscores Quintiles’ commitment to delivering efficient, insightful late phase solutions to help customers show the value of their products to patients, providers and payers,” said Quintiles President and Chief Operating Officer John Ratliff. “The Phase IIIB/IV market is forecast to reach more than $4 billion by 2015, up significantly from 2010.[1] We estimate that observational research accounts for about 30% of that market, and Outcome is a leader in it.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
